TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases.

ABSTRACT:

Clinical trial registration

NCT06048718 (clinicaltrials.gov); 2023 -506,702-39-00 (EudraCT number).

SUBMITTER: Marhold M 

PROVIDER: S-EPMC11988270 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature